Conjunctivitis Treatment Market Report 2026

Conjunctivitis Treatment Market Overview

• Conjunctivitis Treatment market size has reached to $4.89 billion in 2025 • Expected to grow to $6.13 billion in 2030 at a compound annual growth rate (CAGR) of 4.7% • Growth Driver: Increasing Geriatric Population Fueling Growth In The Conjunctivitis Treatment Market • Market Trend: Innovative Product Launches Shaping In The Conjunctivitis Treatment • North America was the largest region in 2025 and Asia Pacific is the fastest growing region.

What Is Covered Under Conjunctivitis Treatment Market?

Conjunctivitis treatment refers to the medical interventions and therapies to manage and resolve the symptoms and underlying causes of conjunctivitis, also known as pink eye. It involves using various medications to reduce inflammation, relieve symptoms, and prevent the spread of the infection. The main types of drugs for conjunctivitis treatment are antibiotics, antivirals, anti-allergic, and artificial tears. Antibiotics are a class of medications used to treat bacterial infections, and they work by either killing bacteria or inhibiting their growth and are commonly prescribed for conjunctivitis caused by bacterial pathogens to reduce inflammation and eradicate bacterial infection. They are used in the treatment of various diseases, such as allergic conjunctivitis, bacterial conjunctivitis, and viral conjunctivitis, administered orally and topically. It is used by end-users, including hospitals, home care, specialty clinics, and others.

What Is The Conjunctivitis Treatment Market Growth Forecast?

The conjunctivitis treatment market size is expected to see steady growth in the next few years. It will grow to $6.13 billion in 2030 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to increasing awareness of eye hygiene, rising self-medication trends, growth of otc ophthalmic products, expanding urban populations, improved access to eye care. Major trends in the forecast period include rising demand for preservative-free eye drops, increased use of combination drug formulations, growth in over-the-counter treatment adoption, focus on faster symptom relief therapies, expansion of homecare-based treatment.

Global Conjunctivitis Treatment Market Segmentation

1) By Drug Class: Antibiotics, Antiviral, Anti-Allergic, Artificial Tears 2) By Disease Type: Allergic Conjunctivitis, Bacterial Conjunctivitis, Viral Conjunctivitis 3) By Route Of Administration: Oral, Topical 4) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users Subsegments: 1) By Antibiotics Conjunctivitis Treatment: Topical Antibiotic Drops, Ointment-Based Antibiotics, Combination Antibiotic Formulations, Preservative-Free Antibiotic Solutions 2) By Antiviral Conjunctivitis Treatment: Topical Antiviral Drops, Oral Antiviral Medications, Combination Antiviral Formulations, Ophthalmic Antiviral Ointments 3) By Anti-Allergic Conjunctivitis Treatment: Antihistamine Eye Drops, Mast Cell Stabilizer Drops, Combination Anti-Allergic Formulations, Preservative-Free Anti-Allergic Solutions 4) By Artificial Tears Conjunctivitis Treatment: Lubricating Eye Drops, Gel-Based Artificial Tears, Preservative-Free Artificial Tears, Combination Moisturizing Formulations

What Is The Driver Of The Conjunctivitis Treatment Market?

An increasing geriatric population is expected to boost the growth of the conjunctivitis treatment market. The geriatric population refers to the elderly or senior citizens within a given society or population. The elderly population is more prone to various eye conditions, including conjunctivitis. Factors such as weakened immune systems, pre-existing medical conditions, and age-related changes in eye health make the elderly more susceptible to infections. For instance, in July 2024, according to the UK Parliament's House of Commons Library, a UK-based government administration, in 2022, there were 12.7 million individuals aged 65 or older in the UK, making up 19% of the total population. By 2072, this number is expected to increase to 22.1 million, comprising 27% of the population. Therefore, the increasing geriatric population is driving the growth of the conjunctivitis treatment industry.

Key Players In The Global Conjunctivitis Treatment Market

Major companies operating in the conjunctivitis treatment market are Alcon Laboratories Inc., Santen Pharmaceuticals Co. Ltd, Eyevance Pharmaceuticals LLC, Johnson and Johnson, Bausch Health Companies Inc., Cipla Inc., Dr Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Lupin Limited, Alembic Pharmaceuticals Ltd., Akorn Inc., Micro Labs Ltd., Ocular Therapeutics Inc., GlaxoSmithKline plc, Merck & Co Inc, Vanda Pharmaceuticals, Aldeyra Therapeutics, Allakos Inc, Regeneron Pharmaceuticals, Marinomed Biotech AG, Eleusis Holdings Ltd, IACTA Pharmaceuticals, Nanomerics, OKYO Pharma, Stuart Therapeutics

Global Conjunctivitis Treatment Market Trends and Insights

Major companies operating in the conjunctivitis treatment market are focusing on product development and launches, such as ophthalmic products, to sustain their position in the market. Ophthalmic products refer to a category of medical and pharmaceutical products specifically designed for the care and treatment of the eyes and vision-related conditions. For instance, in July 2023, Harrow, Inc., a US-based company that operates in ophthalmic healthcare and specializes in pharmaceutical products for ophthalmic surgeries and eye conditions such as dry eye disease, glaucoma, allergies, and infections, unveiled five innovative ophthalmic products in the United States. FLAREX (fluorometholone acetate ophthalmic suspension) 0.1% targets steroid-responsive inflammatory conditions of the eye, while NATACYN (natamycin ophthalmic suspension) 5% stands as the sole FDA-approved topical ophthalmic antifungal medication, addressing fungal blepharitis, conjunctivitis, and keratitis. TOBRADEX ST (tobramycin/dexamethasone ophthalmic suspension) 0.3%/0.05% is designed for inflammatory ocular conditions requiring a corticosteroid, coupled with a risk of bacterial ocular infection. VERKAZIA (cyclosporine ophthalmic emulsion) 0.1%, a patented ‘orphan-designated product’, serves the treatment of vernal keratoconjunctivitis in both children and adults. Lastly, ZERVIATE (cetirizine ophthalmic solution) 0.24% addresses ocular itching associated with allergic conjunctivitis. This comprehensive product launch underscores Harrow, Inc.'s commitment to diverse and targeted solutions for various ophthalmic conditions.

What Are Latest Mergers And Acquisitions In The Conjunctivitis Treatment Market?

In July 2023, Harrow Health Inc., a US-based healthcare company, acquired Santen Pharmaceutical Co., Ltd.'s branded ophthalmic portfolio for an undisclosed amount. With this acquisition, Harrow aimed to expand its North American ophthalmic product portfolio and commercial footprint, enhancing product diversification and revenue streams across the U.S. and Canadian ophthalmic markets. Santen Pharmaceutical Co. Ltd. is a Japan-based pharmaceutical company that specializes in researching, developing and commercializing ophthalmic treatments and products.

Regional Outlook

North America was the largest region in the conjunctivitis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Conjunctivitis Treatment Market?

The conjunctivitis treatment market consists of revenues earned by entities by providing antibiotic therapy and eye-warming therapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The conjunctivitis treatment market also includes sales of eye drops, ointments, ophthalmic steroids, non-steroidal anti-inflammatory drugs, and antihistamines, which are used in conjunctivitis treatment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Conjunctivitis Treatment Market Report 2026?

The conjunctivitis treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the conjunctivitis treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.